Cargando…

Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma

BACKGROUND: In the phase 3 METEOR trial, cabozantinib improved progression-free survival (PFS) and overall survival (OS) versus everolimus in patients with advanced RCC after prior antiangiogenic therapy. METHODS: In this exploratory analysis, plasma biomarkers from baseline and week 4 from 621 of 6...

Descripción completa

Detalles Bibliográficos
Autores principales:	Powles, Thomas, Choueiri, Toni K., Motzer, Robert J., Jonasch, Eric, Pal, Sumanta, Tannir, Nizar M., Signoretti, Sabina, Kaldate, Rajesh, Scheffold, Christian, Wang, Evelyn, Aftab, Dana T., Escudier, Bernard, George, Daniel J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349489/ https://www.ncbi.nlm.nih.gov/pubmed/34364385 http://dx.doi.org/10.1186/s12885-021-08630-w

Ejemplares similares

Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2021)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma
por: Powles, Thomas, et al.
Publicado: (2018)

Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma
por: Donskov, Frede, et al.
Publicado: (2019)

Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
por: Schmidinger, Manuela, et al.
Publicado: (2022)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Cabozantinib in advanced renal cell carcinoma: a METEOR impact on clinical practice
por: Grassi, Paolo, et al.
Publicado: (2016)

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma
por: Msaouel, Pavlos, et al.
Publicado: (2017)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
por: Pal, Sumanta K., et al.
Publicado: (2021)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

Introducing Meteor
por: Robinson, Josh, et al.
Publicado: (2015)

Meteor in action
por: Hochhaus, Stephan, et al.
Publicado: (2016)

Symposium on Meteors
por: Kaiser, T R
Publicado: (1955)

Les météores /
por: Margollé 1816-1884
Publicado: (1867)

Retinal meteor
por: Venkatesh, Ramesh, et al.
Publicado: (2017)

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis
por: Lemke, Emily A., et al.
Publicado: (2019)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Physics of meteoric phenomena
por: Bronshten, V A
Publicado: (1983)

Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
por: Choueiri, Toni K, et al.
Publicado: (2022)

Meteors and how to observe them
por: Lunsford, Robert, et al.
Publicado: (2009)

Meteor showers and their parent comets
por: Jenniskens, Peter
Publicado: (2006)

Advances in Meteoroid and Meteor Science
por: Trigo-Rodríguez, J. M, et al.
Publicado: (2008)

Field Guide to Meteors and Meteorites
por: Norton, O. Richard, et al.
Publicado: (2008)

Leonid Meteor Shower Conference
Publicado: (1999)

Meteor showers: an annotated catalog
por: Kronk, Gary W
Publicado: (2014)

Photoacoustic Sounds from Meteors
por: Spalding, Richard, et al.
Publicado: (2017)

On Meteorical, Stony, and Metalline Substances
por: Klaproth,
Publicado: (1804)

Charles Olivier and the rise of meteor science
por: Taibi, Richard
Publicado: (2017)

Modern Meteor Science An Interdisciplinary View
por: Hawkes, Robert, et al.
Publicado: (2005)

Meteoroids: sources of meteors on Earth and beyond
por: Ryabova, Galina O, et al.
Publicado: (2019)

Meteoric Metal Chemistry in the Martian Atmosphere
por: Plane, J. M. C., et al.
Publicado: (2018)

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
por: George, Daniel J., et al.
Publicado: (2019)

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma
por: Emberley, Ethan, et al.
Publicado: (2021)

Build applications with Meteor: full stack development
por: Ganev, Dobrin
Publicado: (2017)

The stars: including an account of nebulae, comets, and meteors
por: T. Nelson and Sons
Publicado: (1881)

Excellent mechanical properties of taenite in meteoric iron
por: Ueki, Shohei, et al.
Publicado: (2021)

Instant Meteor JavaScript framework starter: enjoy creating a multi-page site, using the exciting new Meteor framework!
por: Manricks, Gabriel
Publicado: (2013)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
por: Bracarda, S, et al.
Publicado: (2012)

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma
por: Sternberg, Cora N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sm831b61sbe7r33pie9an7seo6